Skip to main content
SpringerLink
Log in

Hypertension in Patients with Heart Failure with Reduced Ejection Fraction

  • Hypertension (AJ Peixoto and DS Geller, Section Editors)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Hypertension (HTN) is a well-known health problem associated with considerable morbidity and mortality and it is an important risk factor for the development of heart failure (HF). These findings support the need for optimizing the antihypertensive strategies to prevent the progression to HF. Interestingly, the progression from HTN to HF, among other things, may be a consequence of inappropriate over-activation of the renin–angiotensin–aldosterone system (RAAS), sympathetic nervous system (SNS), and the natriuretic peptide system (NPS). In the present review, we will discuss the pathophysiological aspects of the progression from HTN to HF with reduced ejection fraction (HFrEF) and we will focus on the evolution of different pharmacological therapies which are reported to be effective in reducing BP and improving HF outcomes, paying particular attention to the recent trials that have demonstrated the efficacy of the combined therapy of RAAS blockade and Neprilysin (NEP) inhibitor in lowering BP and mediating several beneficial actions within cardiovascular tissues, such as avoiding the worsening of HF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. PharmacolTher. 2014;144(1):41–9. This article provides a great overview of the several trials carried out to define the role of neprilysin inhibitor in both hypertension and heart failure.

  2. Sahle BW, Owen AJ, Krum H, et al. Second australian national blood pressure study management committee. Incidence of heart failure in 6083 elderly hypertensive patients: the second australian national blood pressure study (ANBP2). Eur J Heart Fail. 2016;18(1):38–45.

    Article  PubMed  Google Scholar 

  3. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens. 2008;26:477–86.

    Article  Google Scholar 

  4. Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123:327–34.

    Article  PubMed  Google Scholar 

  5. von Lueder TG, Krum H. RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc Drugs Ther. 2013;27:171–9.

    Article  CAS  Google Scholar 

  6. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch Intern Med. 1996;156:1789–96.

    Article  CAS  PubMed  Google Scholar 

  7. Hoffman JI. Maximal coronary flow and the concept of coronary vascular reserve. Circulation. 1984;70:153–9.

    Article  CAS  PubMed  Google Scholar 

  8. Ross Jr J. On variations in the cardiac hypertrophic response to pressure overload. Circulation. 1997;95:1349–51.

    Article  PubMed  Google Scholar 

  9. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med. 2008;358:1370–80.

    Article  CAS  PubMed  Google Scholar 

  10. Diez J, Frohlich ED. A translational approach to hypertensive heart disease. Hypertension. 2010;55:1–8.

    Article  CAS  PubMed  Google Scholar 

  11. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345(23):1689–97.

    Article  CAS  PubMed  Google Scholar 

  12. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27:47–72.

    Article  CAS  PubMed  Google Scholar 

  13. • von Lueder TG, Sangaralingham SJ, Wang BH, et al. Renin–angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail. 2013;6:594–605. This article provides the role of ARNIs in regulating the cardiovascular effects of RAAS.

  14. Atlas SA. The renin–angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(Suppl S-b):S9–20.

    Google Scholar 

  15. Macía-Heras M, Del Castillo-Rodríguez N, Navarro González JF. The renin–angiotensin–aldosterone systemin renal and cardiovascular disease and the effects of its pharmacological blockade. J Diabetes Metab. 2012;3:171.

    Google Scholar 

  16. Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: novel means for renin–angiotensin–aldosterone system modulation and emerging device-based approaches. Eur Heart J. 2011;32:2739–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.

    Article  CAS  PubMed  Google Scholar 

  18. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.

    Article  PubMed  Google Scholar 

  19. Volpe M. Natriuretic peptides and cardio-renal disease. Int J Cardiol. 2014;176(3):630–9.

    Article  PubMed  Google Scholar 

  20. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33:1058–66.

    Article  CAS  PubMed  Google Scholar 

  21. Fisher JP, Paton JF. The sympathetic nervous system and blood pressure in humans: implications for hypertension. J Hum Hypertens. 2012;26:463–75.

    Article  CAS  PubMed  Google Scholar 

  22. Schrier RW, Abdallah JG, Weinberger HH, et al. Therapy of heart failure. Kidney Int. 2000;57:1418–25.

    Article  CAS  PubMed  Google Scholar 

  23. Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54:1747–62.

    Article  CAS  PubMed  Google Scholar 

  24. Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension. 2003;41:383–9.

    Article  CAS  PubMed  Google Scholar 

  25. Clerico A, Recchia FA, Passino C, et al. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol. 2006;290:H17–29.

    Article  CAS  PubMed  Google Scholar 

  26. Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J. 2011;278:1808–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Chen HH, Schirger JA, Chau WL, et al. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation. 1999;100:2443–8.

    Article  CAS  PubMed  Google Scholar 

  28. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet. 2003;362(9386):759–66.

    Article  CAS  PubMed  Google Scholar 

  29. Smith S, Rossignol P, Willis S, et al. Neural modulation for hypertension and heart failure. Int J Cardiol. 2016;214:320–30.

    Article  CAS  PubMed  Google Scholar 

  30. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131n(4):e29–322.

    Article  Google Scholar 

  31. Sartipy U, Dahlstrom U, Edner M, et al. Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51043 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2014;16(2):173–9.

    Article  PubMed  Google Scholar 

  32. Palano F, Paneni F, Sciarretta S, et al. The progression from hypertension to congestive heart failure. Recenti Prog Med. 2011;102(12):461–7.

    PubMed  Google Scholar 

  33. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41–6.

    Article  PubMed  Google Scholar 

  34. ALLHAT Collaborative Research Group. Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981–97.

    Article  Google Scholar 

  35. Julius S, Kjeldsen S, Weber M, et al. Outcomes in hypertension patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–31.

    Article  CAS  PubMed  Google Scholar 

  36. Cohn JN, Tognoni G. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75.

    Article  CAS  PubMed  Google Scholar 

  37. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.

    Article  CAS  PubMed  Google Scholar 

  38. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.

    Article  CAS  PubMed  Google Scholar 

  39. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril onmortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669–77.

    Article  CAS  PubMed  Google Scholar 

  40. Sciarretta S, Palano F, Tocci G, et al. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med. 2011;171(5):384–94.

    PubMed  Google Scholar 

  41. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158998 patients. Eur Heart J. 2012;33:2088–97.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Nathisuwan S, Talbert RL. A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure. Pharmacotherapy. 2002;22:27–42.

    Article  CAS  PubMed  Google Scholar 

  43. Rubattu S, Sciarretta S, Valenti V, et al. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens. 2008;21:733–41.

    Article  CAS  PubMed  Google Scholar 

  44. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet. 2000;356:608–9.

    Article  CAS  PubMed  Google Scholar 

  45. McDowell G, Coutie W, Shaw C, et al. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol. 1997;43:329–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103–11.

    Article  CAS  PubMed  Google Scholar 

  47. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356:615–20.

    Article  CAS  PubMed  Google Scholar 

  48. Fryer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol. 2008;153(5):947–55.

    Article  CAS  PubMed  Google Scholar 

  49. • Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2(6):663–70. This paper describes the role of ARNIs in treating HF progression.

  50. •Gradman AH. LCZ696: the next step in improving RAS inhibition? Curr Hypertens Rep. 2015;17(5):37. This article describes the mechanisms through which LCZ696 has been proved to be a potent, effective antihypertensive agent and, at the meantime able to improve heart failure outcome.

  51. Ruilope LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255–66.

    Article  CAS  PubMed  Google Scholar 

  52. • Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebocontrolled study. Hypertension. 2014;63:698–705. This is one of the two most important trials that defined the role of ARNIs in hypertensive patients.

  53. Katsuya T, Ishikawa K, Sugimoto K, et al. Salt sensitivity of Japanese from the viewpoint of gene polymorphism. Hypertens Res. 2003;26:521–5.

    Article  PubMed  Google Scholar 

  54. Wang JG, Kario K, Lau T, et al. Asian Pacific Heart Association. Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: a scientific statement from the Asian Pacific Heart Association. Hypertens Res. 2011;34:423–30.

    Article  CAS  PubMed  Google Scholar 

  55. • Williams B, Cockcroft JR, Kario K, et al. Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study. BMJ. 2014;Open 4:e004254. This trial, currently ongoing, wants to demonstrate the role of LCZ696 in reversing some of the effects of arterial ageing in elderly patients with systolic hypertension.

  56. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–95.

    Article  CAS  PubMed  Google Scholar 

  57. Vilela-Martin JF. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date. Drug Des Devel Ther. 2016;10:1627–39.

    Article  PubMed  PubMed Central  Google Scholar 

  58. • Filippatos G, Farmakis D, Parissis J, et al. Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice. BMC Med. 2015;13:35. This article focuses on the effects of LCZ696 on the HF progression and on the need of further trial to evaluate the effects of this drug, such as PARAGON-HF trial.

  59. • Katsanos S, Bistola V, Parissis JT. Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure. Expert Rev Clin Pharmacol. 2016;29:1–11. This paper describes the role of ARNIs in treating HF progression.

  60. •• McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. This paper describes the most important double-blind trial that demonstrated the superiority of LCZ696 in reducing the rate of all-cause death compared to enalapril in HFrEF.

  61. Volpe M, Battistoni A, Mastromarino V. Natriuretic peptides and volume handling in heart failure: the paradigm of a new treatment. Eur J Heart Fail. 2016;18(4):442–4.

    Article  PubMed  Google Scholar 

  62. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Unit, Department of Clinical and Molecular Medicine, School of Medicine and Psychology, University Sapienza of Rome, S. Andrea Hospital, Rome, Italy

    Massimo Volpe, Caterina Santolamazza & Giuliano Tocci

  2. IRCSS – Neuromed, Pozzilli, IS, Italy

    Massimo Volpe & Giuliano Tocci

Authors
  1. Massimo Volpe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caterina Santolamazza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuliano Tocci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Volpe.

Ethics declarations

Conflict of Interest

Massimo Volpe has served on the advisory board of Novartis for the last three years.

Caterina Santolamazza and Giuliano Tocci declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hypertension

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Volpe, M., Santolamazza, C. & Tocci, G. Hypertension in Patients with Heart Failure with Reduced Ejection Fraction. Curr Cardiol Rep 18, 127 (2016). https://doi.org/10.1007/s11886-016-0807-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-016-0807-9

Keywords

Search

Navigation